What is CVE-2023-33364?

CVE-2023-33364 is a high-severity vulnerability in Supremainc Biostar 2, classified under OS Command Injection. CVSS score: 8.8/10. Published 2023-08-03.

How severe is CVE-2023-33364?

High severity. CVSS v3 base score is 8.8 out of 10.

RCE in Supremainc Biostar 2

CVE-2023-33364

An OS Command injection vulnerability exists in Suprema BioStar 2 before V2.9.1, which allows authenticated users to execute arbitrary OS commands on the BioStar 2 server.

Vulnerability class: Command Injection (OS Command Injection)

Published 2023-08-03 · last modified 2026-06-17.

CVSS v3 metric

CVSS v3 base score 8.8 (High). Vector: CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H.

EPSS exploit prediction

EPSS: 0.016 (75.2th percentile), scored 2026-10-29.

Low probability of exploitation in the next 30 days, but still tracked. 75th percentile — 75.2% of CVEs in the catalogue have a lower EPSS than this one. How to read EPSS.

EPSS over last 30 days · oldest: 0.016 · newest: 0.016 · change: 0.000

Affected products

Supremainc Biostar 2

Weakness classification (CWE)

CWE-78 — OS Command Injection

References

kb.supremainc.com/knowledge/doku.php (Release Notes, Vendor Advisory)
claroty.com/team82/disclosure-dashboard/cve-2023-33364 (Third Party Advisory)

Frequently asked questions

What is CVE-2023-33364?: CVE-2023-33364 is a high-severity vulnerability in Supremainc Biostar 2, classified under OS Command Injection. CVSS score: 8.8/10. Published 2023-08-03.
How severe is CVE-2023-33364?: High severity. CVSS v3 base score is 8.8 out of 10.